349 related articles for article (PubMed ID: 28675766)
1. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients.
Bao L; Wang Y; Lu M; Chu B; Shi L; Gao S; Fang L; Xiang Q
Cancer Med; 2020 Dec; 9(23):8962-8969. PubMed ID: 33145966
[TBL] [Abstract][Full Text] [Related]
3. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.
Trakada G; Kastritis E; Gavriatopoulou M; Velentza L; Fotiou D; Ziogas DC; Panagiotidis I; Eleutherakis-Papaiakovou E; Roussou M; Migkou M; Kanellias N; Ntanasis-Stathopoulos I; Kallianos A; Terpos E; Dimopoulos MA
Ann Hematol; 2019 Jun; 98(6):1427-1434. PubMed ID: 30834954
[TBL] [Abstract][Full Text] [Related]
5. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
[TBL] [Abstract][Full Text] [Related]
7. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
9. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
11. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
[TBL] [Abstract][Full Text] [Related]
12. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.
Gkotzamanidou M; Kastritis E; Gavriatopoulou MR; Nikitas N; Gika D; Mparmparousi D; Matsouka C; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):409-13. PubMed ID: 21903504
[TBL] [Abstract][Full Text] [Related]
13. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
14. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
15. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with multiple myeloma and renal failure on novel regimens.
Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
[TBL] [Abstract][Full Text] [Related]
18. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.
Terpos E; Ntanasis-Stathopoulos I; Christoulas D; Bagratuni T; Bakogeorgos M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Dimopoulos MA
Blood Cancer J; 2018 May; 8(5):42. PubMed ID: 29748532
[TBL] [Abstract][Full Text] [Related]
19. Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.
Gonsalves WI; Godby K; Kumar SK; Costa LJ
Am J Hematol; 2016 Jan; 91(1):101-8. PubMed ID: 26214377
[TBL] [Abstract][Full Text] [Related]
20. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Zeldenrust SR; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Leuk Lymphoma; 2019 Dec; 60(12):2960-2967. PubMed ID: 31096812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
